GlassScriptPhysician profile
Hillary H Wu
NPI 1881686848
$7,269.64
in general payments reported to CMS, 2019-2025
45 companies · $424 in 2025
The $424 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,989 · 2020: $1,314 · 2021: $33.23 · 2022: $2,922 · 2023: $226 · 2024: $361 · 2025: $424.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,012.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,011.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Roche Diagnostics Corporation | $2,800.00 | 2022 | |
| Exelixis INC. | $1,297.27 | 2019-2025 | Cabometyx |
| Pfizer INC. | $462.56 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $399.27 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $276.44 | 2019-2025 | Lynparza, Enhertu, Tagrisso |
| E.R. Squibb & Sons, L.L.C. | $221.71 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $195.98 | 2019 | |
| Amgen INC. | $181.69 | 2019-2023 | Kyprolis, Blincyto |
| Janssen Biotech, INC. | $105.89 | 2019-2020 | |
| Celgene Corporation | $105.59 | 2019-2022 | |
| Abbvie INC. | $87.66 | 2019-2025 | |
| Eisai INC. | $82.70 | 2019 | |
| Genentech USA, INC. | $81.76 | 2019-2025 | Venclexta |
| Gilead Sciences, INC. | $65.48 | 2019-2025 | Trodelvy |
| Genzyme Corporation | $54.86 | 2019-2020 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hillary Wu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.